Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world.

Pfizer’s forecast for sales of its COVID-19 vaccine and treatment next year falls more than $5 billion short of the Wall Street consensus.

The fallout from the Israel-Hamas war has spilled into workplaces everywhere, with corporate leaders from the highest ranks of prominent companies weighing in with their views while workers complain their voices are not being heard.

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.

Pfizer says it will provide nearly two dozen products at not-for-profit prices in some of the world’s poorest countries.

Sales of Pfizer’s COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61%.

Pfizer's chief executive, Albert Bourla, has been awarded the prestigious Genesis Prize for his efforts in leading the development of a COVID-19 vaccine.

Pfizer announced on Wednesday that preliminary research suggests its booster shots are effective against the omicron variant. They also warned that just two doses may not be sufficient.

The U.S. has given full approval to the COVID-19 vaccine made by Pfizer.

Japan’s prime minister met with Pfizer’s CEO in an unusually high-profile setting to make sure the drugmaker would deliver COVID-19 vaccine it has promised to the nation.

The husband and wife team who helped develop the first COVID-19 vaccine are contributing to a book.

Pfizer Chairman and CEO Dr. Albert Bourla can now look back and tell the incredible story.

A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots.

Japan's prime minister has asked U.S. drug maker Pfizer for additional supplies of the COVID-19 vaccine.

I know what it’s like to not be there when it happens," said Biden, who has long addressed grief more powerfully than perhaps any other American public figure. "I know what it’s like when you are there, holding their hands, as they look in your eye and they slip away. In one of his many symbolic breaks with his predecessor, Biden has not shied away from offering remembrances for the lives lost to the virus. The COVID-19 death total in the United States had just crossed 400,000 when Biden took the oath of office. Outside of perfunctory tweets marking the milestones of 100,000 and 200,000 deaths, Trump oversaw no moment of national mourning, no memorial service.

On Monday, Nov. 9, 2020, Pfizer said an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19. Pfizer released no specific breakdowns, but for the vaccine to be 90% effective, nearly all the infections must have occurred in placebo recipients. The study is continuing, and Pfizer cautioned that the protection rate might change as more COVID-19 cases are added to the calculations. REPORT 90% EFFECTIVE. Earlier this year, Fauci said he would be happy with a COVID-19 vaccine that was 60% effective.

Pfizer executives had expected data from their 44,000-person international study would show by Oct. 31 how well it prevents coronavirus infections. Analysts peppered Bourla and other Pfizer executives with so many questions about the study that he repeatedly asked for their patience. It expects revenue of $48.8 billion to $49.5 billion, narrowed from its previous forecast of $48.6 billion to $50.6 billion. Pfizer will receive about $12 billion in return and its shareholders will get roughly one Viatris share for each Pfizer share they own. Pfizer expects to be able to grow revenue at least 6% annually through 2025 as a result of the transformation.

NEW YORK – Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday. Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25. Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company’s vaccine actually protects against the coronavirus. The vaccine made by Pfizer and its German partner BioNTech are among several leading candidates in final testing. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.

Despite top U.S. federal health officials repeatedly stating that a vaccine is unlikely to be available widely until mid-2021, President Donald Trump has insisted that a vaccine will be ready before Election Day. “I’ve spoken to Pfizer, I’ve spoken to all of the people that you have to speak to, Moderna, Johnson & Johnson, and others. “It’s become very political.”“We’re weeks away from a vaccine,” Trump added. Johnson & Johnson just started the final study of its vaccine last week. ___Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.

After concern arose that the development of a coronavirus (COVID-19) vaccine might be rushed for reasons other than public health, vaccine manufacturers have joined together to assure the public that no corners will be cut. READ: Whitmer signs bill to cover $300 weekly unemployment bonus for Michiganders during pandemicThe race to develop a vaccine for COVID-19 is now powered by the joint pledge by manufacturers. A USA Today poll found two-thirds of participants said they wont get a coronavirus vaccine as soon as it comes out. Pfizer officials have said theres a chance that phase three data for their vaccine candidate might be available by the end of October, but thats a big leap. Most experts are looking toward the end of 2020, and keep in mind, once a vaccine is available, the actual distribution is still a complicated process.